Imipramin Neuraxpharm (Imipramine Hydrochloride)

Imipramine hydrochloride inhibits the reuptake of the neurotransmitters norepinephrine and serotonin at neuronal synapses. By preventing their removal from the synaptic cleft, the drug raises their concentrations, enhancing monoaminergic signaling that is associated with mood elevation and anxiolytic effects.

The appropriate dose of Imipramin Neuraxpharm is determined by the prescribing clinician based on the patient’s condition, age, response to therapy, and tolerability. Dosage adjustments are made individually, and patients should follow the prescriber’s instructions without self‑adjusting the amount.

Safety data for imipramine during pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant. Healthcare providers must evaluate each case and discuss possible risks with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Imipramin Neuraxpharm belongs to the tricyclic antidepressant class, which differs from newer agents such as SSRIs and SNRIs. Tricyclics generally have a broader pharmacologic profile, including anticholinergic effects, and may be effective when newer agents are insufficient, but they often require more careful monitoring for side effects.

Imipramin Neuraxpharm should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat, and direct sunlight to maintain its stability and potency.

The medication is taken orally, usually as a tablet, with or without food as directed by the prescriber. Swallow the tablet whole with a full glass of water and follow the dosing schedule provided by the healthcare professional.

Serious risks include cardiac arrhythmias, seizures, severe hypotension, and the potential for suicidal thoughts, especially during early treatment or dose changes. Patients should be monitored closely for any cardiovascular symptoms or changes in mood.

Imipramin Neuraxpharm is contraindicated in patients with recent myocardial infarction, known hypersensitivity to imipramine or other tricyclics, and those currently taking monoamine oxidase inhibitors. Caution is also advised for individuals with severe liver disease, glaucoma, or a history of seizures.